Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 95%
filed 2026-07-14
EX-99.1
This is a press release announcing second-quarter 2026 production results for Trekor's Gibraltar and Florence Copper operations. The disclosure reports specific production volumes (30.3 million pounds of copper from Gibraltar, 5.2 million pounds from Florence Copper), sales figures, and updated annual guidance (110–115 million pounds for Gibraltar; 30–35 million pounds for Florence Copper). This is a discrete operational and financial results announcement typical of an earnings release, material to investors assessing the company's operational performance and ability to meet guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-14
Item 2.02
America's Car-Mart issued a press release on July 14, 2026 announcing operating results for the fourth quarter and fiscal year ended April 30, 2026, disclosing total revenue of $1,281.5 million (down 7.9%), sales volumes of 48,891 units (down 14.3%), and a loss per share of $16.79. This is a standard earnings release disclosure under Item 2.02, attached as Exhibit 99.1 and furnished in accordance with General Instruction B.2.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-14
Item 1.01
Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America on July 10, 2026, establishing a $50.0 million senior revolving line of credit with a maturity date of July 10, 2031, and an option to request up to an additional $50.0 million for a maximum of $100.0 million.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
Tower Semiconductor announces a strategic dual-track capacity expansion in Japan with Government of Japan (METI) support, involving repurposing the Arai facility for 300mm Silicon Photonics and constructing an adjacent new 300mm manufacturing facility. The company updates its 2028 business model to target $3.6 billion revenue and $1.2 billion net profit, with approximately $3 billion in Tower investment net of $1 billion in government grants. This is a material operational and strategic business event involving significant capital investment, facility expansion, and revised financial guidance, but does not fit the specific categories of M&A activity, debt issuance, or other named event types.
View raw filing on EDGAR →
6-K
Cybersecurity Incident
confidence 95%
filed 2026-07-14
The 6-K discloses a material cybersecurity incident involving unauthorized exfiltration of backup data, including payment transaction records and business information, following an initial announcement on July 8, 2026. Although the Company confirms systems are now cleared, production environment unimpacted, and customer funds untouched, the incident involved data exfiltration, criminal extortion demands, and ongoing investigation costs—hallmarks of a material cybersecurity breach requiring disclosure under Item 1.05 (required since 2023).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
TAT Technologies announced an expansion of its strategic relationship with Honeywell Aerospace, becoming the sole global authorized distributor of spare parts for the GTCP 331-200/250 APU platform, extending MRO licenses until 2036, and acquiring three APUs for its trading and leasing business. This is a material operational and commercial milestone—a significant partnership expansion and distribution agreement—that does not fit the specific event categories (M&A, debt, equity, litigation, etc.) but clearly affects the registrant's business strategy and revenue prospects in its core aerospace aftermarket segment.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-14
EX-99.1
SuperCom announced a registered direct offering of 732,683 ordinary shares at $10.25 per share, raising approximately $7.5 million in gross proceeds. This is a registered equity issuance under the company's Form F-3 shelf registration statement, which dilutes existing shareholders. The offering is material to investors as it represents a significant capital raise and shareholder dilution event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
QTREX announced receipt of a commercial purchase order from a leading international government-owned company for customized Shielded RF Monolithic components. The disclosure emphasizes this as a strategic expansion of the company's commercial model into direct supply of proprietary, application-specific components, with production underway and delivery expected within days. While this is a material operational and commercial milestone demonstrating market validation and revenue generation, it does not fit the specific event-type categories (not M&A, not a financial obligation, not a restructuring). This is a material contract/commercial milestone that would affect a reasonable investor's assessment of the company's business trajectory and revenue prospects.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-14
The 6-K discloses the results of an extraordinary general meeting of shareholders held on July 14, 2026, with detailed voting tallies for five proposals. All proposals passed, including a significant increase in authorized share capital (from US$50,000 to US$2,500,000), approval of share consolidations at ratios between 1-for-10 and 1-for-250, and amendments to the memorandum and articles of association. These capital structure changes are material to investors' assessment of the company's equity and voting rights.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-14
Item 5.07
This Item 5.07 disclosure reports the results of the Company's annual stockholder meeting held on July 8, 2026, including election of two Class I Directors (Bradley V. Stoots and Steven G. Hooser), ratification of HoganTaylor LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents voting tallies for each matter, which is the core content of shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-14
Item 2.02
Unity Bancorp issued a press release on July 14, 2026 announcing quarterly and six-month financial results for the period ended June 30, 2026. The disclosure includes net income of $14.5 million ($1.42 per diluted share) for Q2 2026 and $28.8 million ($2.82 per diluted share) for the six-month period, along with detailed financial highlights, balance sheet data, and performance metrics. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-14
Item 2.02
SemiLEDs issued a press release on July 14, 2026 announcing preliminary financial results for the third quarter ended May 31, 2026, disclosing revenue of $9.1 million, GAAP net income of $1.5 million ($0.18 per diluted share), and key metrics including gross margin (27%) and operating margin (16%). The filing includes unaudited condensed consolidated balance sheets and statements of operations, which are typical exhibits for quarterly earnings releases under Item 2.02.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-07-14
Item 7.01
Mercer Torgau, an indirectly wholly-owned subsidiary of Mercer International Inc., announced strategic actions involving a workforce reduction of approximately 350 positions overall, with an initial reduction of approximately 100 contractor positions in July 2026, to be completed in stages by Q2 2027. The disclosure explicitly addresses operational restructuring and workforce reduction, which are material to investors assessing the registrant's operational efficiency and cost structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-14
Item 8.01
CleanSpark entered into a 20-year triple-net lease agreement with a high-investment-grade global technology company for 175 MW of data center infrastructure at its Sandersville, Georgia campus, generating $6.6 billion in contracted revenue over the initial term with up to $11.6 billion including extension options, plus an exclusivity arrangement covering its 885 MW Texas portfolio. This represents a transformational operational and strategic milestone for the company's data center business model.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 1.01
Spero entered into an exclusive license agreement with Innovent Biologics on July 8, 2026, acquiring worldwide rights (excluding Greater China) to develop, manufacture, and commercialize SP001, a Phase 2-ready anti-CD40L monoclonal antibody. The transaction includes an upfront payment of $35 million, up to $1.05 billion in milestone payments, and tiered royalties, establishing the foundation of Spero's new immunology pipeline.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-14
Item 2.03
Spero entered into a $105 million non-recourse royalty financing transaction with Healthcare Royalty (a KKR affiliate), receiving $105 million in exchange for rights to future milestone and royalty payments from Utebzi sales, with Healthcare Royalty receiving quarterly principal and interest payments derived from GSK payments.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-14
EX-99.1
Apollomics announced on July 8, 2026, that it "regained compliance" with Nasdaq's Market Value of Listed Securities (MVLS) requirement after receiving a non-compliance notice on June 18, 2026, for failing to maintain the $35 million minimum. The press release explicitly states "the matter is now closed," confirming resolution of a delisting risk that threatened the company's continued listing on the Nasdaq Capital Market.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
Thomson Reuters has signed a definitive agreement to enter into a joint venture with KKR, selling a 51% stake in its Global Print business for approximately $500 million in gross proceeds while retaining 49% equity interest. This constitutes a material disposition and change of control of a business segment, directly falling under Item 1.01/1.02 (M&A activity). The transaction is substantial, involves a major investment firm, and is expected to close in Q4 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-14
Item 2.02
HCA Healthcare issued a press release on July 14, 2026 announcing preliminary financial results for Q2 2026, including revenues of $20.230 billion, net income of $1.699 billion ($7.62 per diluted share), and Adjusted EBITDA of $4.027 billion, along with revised 2026 full-year guidance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-14
Item 8.01
Inhibikase announced the sale of 25 million shares of common stock for $50 million gross proceeds through its at-the-market (ATM) facility to RA Capital Management. This is a registered equity issuance under a shelf registration statement (Form S-3) and ATM prospectus supplement. The sale is material to investors as it represents significant dilution and capital raising activity for a clinical-stage pharmaceutical company, and the proceeds are earmarked to fund operations through a key clinical milestone (Phase 3 IMPROVE-PAH topline data readout).
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 1.01
Diodes Incorporated entered into a definitive Agreement and Plan of Merger on July 10, 2026, to acquire Elevate Semiconductor, Inc. for a $250 million base purchase price plus up to $50 million in earnout payments. The all-cash transaction is expected to contribute approximately $50 million in revenue in the first twelve months post-close and be immediately accretive to revenue, gross margin, and earnings per share.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-14
Item 7.01
The disclosure centers on Runway Growth's Q2 2026 portfolio activity and capital allocation strategy, including $85.8 million in new fundings, portfolio composition updates (59 debt and 102 equity investments), and a strategic commitment by the adviser and insiders to purchase up to 10% of outstanding shares over 24 months alongside a $15 million company repurchase program. While the filing includes operational metrics (originations, liquidity events, portfolio construction), the core material event is the capital allocation strategy and insider commitment to share purchases, which is a strategic business decision rather than a discrete financial transaction (debt issuance, M&A, etc.) or governance action. This is material to investors as it signals management confidence and affects capital deployment priorities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 8.01
Syndax disclosed an R&D event on July 14, 2026, highlighting late-stage programs and unveiling two new pipeline assets: SNDX-4321 (a novel allosteric EGFR inhibitor for NSCLC with IND submission expected by end of 2026 and Phase 1 initiation in 2027) and SNDX-62122 (a next-generation menin inhibitor for myelofibrosis with IND submission and Phase 1 expected in 2027). This represents a material strategic expansion of the company's pipeline with new differentiated assets supported by preclinical data, which would affect a reasonable investor's assessment of the company's R&D capabilities and growth opportunities. The event is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-14
Item 2.01
flyExclusive completed a material acquisition of Jet.AI's aviation assets on July 14, 2026, pursuant to Amendment No. 5 to the Amended and Restated Merger Agreement executed on July 13, 2026. The transaction involved a merger of Merger Sub into SpinCo (a Jet.AI entity), with SpinCo becoming a wholly owned subsidiary of flyExclusive, and consideration consisting of 7,096,117 shares of Company Common Stock, aircraft, customer relationships, future aircraft delivery positions, SPCX marketable securities, and cash.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 2.01
On July 14, 2026, Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation, with stockholders receiving $39.00 per share in cash plus contingent value rights tied to pending litigation proceeds. The transaction constitutes a material change of control and merger completion, with the company's stock delisted from Nasdaq and registration to be terminated via Form 15.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Following the completion of the Ligand Pharmaceuticals acquisition, XOMA Royalty notified Nasdaq to halt trading and delist its shares effective July 14, 2026, and intends to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-14
Item 5.07
At a Special Meeting of Stockholders held on July 13, 2026, stockholders approved three proposals: the Merger Agreement (15,924,106 votes for), the Holding Company Reorganization (15,924,259 votes for), and the Compensation Proposal (15,745,257 votes for), all related to the Ligand Pharmaceuticals acquisition.
View raw filing on EDGAR →
8-K
Governance Other
confidence 95%
filed 2026-07-14
Item 5.02
Effective upon the completion of the Ligand Pharmaceuticals acquisition, all prior directors of XOMA Royalty resigned and were replaced by Merger Sub's directors and officers, reflecting the change of control and board transition resulting from the merger closing.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Pittsburgh. Schedule A details multiple debt issuances with trade dates of 7/8/2026 through 7/10/2026, including variable-rate floaters totaling $1.46 billion and fixed-rate bonds totaling approximately $38 million. The registrant explicitly states that "consolidated obligations issuance is material to the FHLBank," confirming the materiality of this debt creation event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 1.01
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation on July 14, 2026, for $39.00 per share in cash (approximately $739 million equity value) plus contingent value rights. The transaction doubles Ligand's royalty portfolio from approximately 100 to over 200 assets, adds seven commercial products and 14 late-stage development programs, and is expected to be accretive to earnings per share by $0.50 and $1.50 in 2026 and 2027 respectively.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
Navigator Holdings announced the signing of definitive agreements to sell eight gas carriers and its shareholding in the Unigas Joint Venture for approximately $183 million to existing Unigas partners. This is a material disposition transaction involving the sale of significant fleet assets and a joint venture stake, expected to close by Q4 2026. The transaction represents a substantial capital event affecting the company's fleet composition and financial position.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-07-14
Item 7.01
Management made a material misstatement of full-year Adjusted EBITDA guidance during a July 13 conference call, citing $330-$345 million instead of the correct $335-$350 million stated in the prior press release. This disclosure corrects the error and clarifies that guidance remains unchanged. While the event involves guidance correction, it does not fit neatly into earnings_release (no new results disclosed) or other specific categories; it is a material disclosure of a management error affecting investor reliance on publicly stated guidance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 82%
filed 2026-07-14
Item 1.01
Fidelity Private Credit Co LLC entered into a Fifth Amendment to its Loan and Security Agreement, materially restructuring its credit facility by converting $200 million in Tranche B commitments from term loan to revolving loan commitments and reducing Tranche A commitments from $800 million to $500 million. The amendment contemplates Fund II's assumption of all obligations upon merger consummation, constituting a material modification and refinancing of the Fund's direct financial obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 45%
filed 2026-07-14
Item 1.01
The filing discloses entry into registration rights agreements following conversion of $15 million in Senior Secured Convertible Promissory Notes into 1.54 million common shares. While the registration rights agreements themselves are ancillary to the underlying debt conversion, the Item 1.01 disclosure centers on the creation of registration obligations tied to a material debt instrument. However, the debt was issued in January and February 2025 and converted in March 2026; the July 2026 filing documents only the registration rights agreement entered into post-conversion, which is a secondary contractual arrangement rather than a primary debt issuance or material M&A event. This is a borderline case between debt_issuance (the original notes, now converted) and financial_other (the registration rights agreement itself).
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 93%
filed 2026-07-14
Item 1.01
Wabash National entered into a Fifth Amendment to its Credit Agreement permitting up to $150 million in additional indebtedness and commenced a private offering of $100 million aggregate principal amount of convertible senior unsecured notes due 2032 (with an option for an additional $15 million), representing a material creation of new direct financial obligations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-14
Item 2.02
Phoenix Education Partners issued a press release on July 14, 2026, reporting financial results for the three and nine months ended May 31, 2026 and 2025, disclosing net revenue of $271.8 million for Q3 2026, net income of $39.2 million ($1.01 diluted EPS), and providing fiscal year 2026 guidance. This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the company's financial performance and operational trends.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-14
Item 5.02
Zachary F. Sadek was appointed to the Board of Directors effective July 13, 2026, pursuant to a Cooperation Agreement with PCP Managers II, L.P. (Parthenon Capital), one of the Company's largest stockholders, expanding the board from six to seven members.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-14
Item 1.01
Kestra Medical Technologies entered into a $200 million senior secured term loan facility on July 10, 2026, with $75 million funded immediately (Tranche A), replacing its prior loan agreement. The new facility has customary covenants, security interests in substantially all assets, and a five-year maturity, representing a material refinancing that fortified the company's balance sheet.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-14
Item 2.02
Kestra Medical Technologies disclosed financial results for the fourth quarter and fiscal year ended April 30, 2026, reporting revenue of $95.1 million (59% year-over-year growth), gross margin expansion to 51.4%, and fiscal 2027 revenue guidance of $137 million. The disclosure includes consolidated financial statements and detailed financial highlights.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-14
Item 2.02
Equity Bancshares issued a press release on July 14, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing net income of $26.4 million ($1.27 per diluted share) and core EPS of $1.41, along with an investor call presentation to discuss the quarterly results.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-14
Item 8.01
Paramount Gold Nevada Corp. filed a technical report summary for its Grassy Mountain Gold Project prepared in accordance with SEC Regulation S-K subpart 1300. This is a comprehensive feasibility study covering mineral resources, reserves, mining methods, processing, infrastructure, environmental permitting, and economic analysis. While not fitting neatly into standard event categories, this represents a material operational milestone—the completion and disclosure of a detailed technical and economic assessment of a major mining project that would inform investors' understanding of the project's viability and development status.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-07-14
Item 8.01
Palmer Square Capital BDC Inc. discloses management's unaudited estimate of net asset value (NAV) per share as of June 30, 2026 ($13.21). For a Business Development Company, NAV is a critical metric for investor valuation and pricing. While this appears to be a routine periodic disclosure, the NAV estimate is material to investors assessing the fund's performance and share value. However, the disclosure does not fit neatly into standard 8-K event categories (not earnings, not a restatement, not a going-concern issue), warranting classification as other_material.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-14
Item 1.01
Jaguar Health's subsidiary Napo entered into a new three-year manufacturing and supply agreement with Alivus on July 9, 2026, to continue supplying crofelemer for Mytesi®, the company's FDA-approved prescription drug product. This is a material definitive agreement that secures the supply chain for the company's primary commercial product and includes minimum purchase commitments with potential financial obligations. While this is a renewal rather than a new relationship, the binding three-year commitment with specified minimum quantities and financial penalties for shortfalls constitutes a material agreement affecting the company's operational and financial obligations.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-14
Item 2.02
The Board declared a cash distribution of $0.09 per share to stockholders. This routine dividend distribution is material to investors as it affects shareholder returns and capital allocation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Trinity Capital announced on July 14, 2026, its intention to voluntarily transfer the listings of its common stock and senior notes from Nasdaq to the New York Stock Exchange and NYSE Texas, with trading expected to commence on or about July 27, 2026. This strategic relisting involves changes to ticker symbols and trading venues for both securities.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Apollo-managed funds completed the acquisition of Emerald Holding, Inc. on July 14, 2026, for $5.03 per share in cash, resulting in a change of control and the cessation of Emerald's NYSE trading. The transaction also included the acquisition of Questex, LLC, creating a combined B2B experiential events and media platform, with Emerald becoming a wholly-owned subsidiary and its board members ceasing service.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-14
Item 5.07
This is a classic Item 5.07 disclosure reporting the final certified voting results from Gloo Holdings' 2026 annual meeting of stockholders held on July 13, 2026. The filing presents tabulated results for two proposals: election of three directors (Bishop Claude Alexander, Jr., John Furst, and Derek Green) and ratification of Crowe LLP as independent auditor. The disclosure includes vote counts (For, Against/Withheld, Abstentions, and Broker Non-Votes) certified by the inspector of elections, which is the standard format for shareholder vote results under Item 5.07.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Ares Real Estate funds completed an all-cash acquisition of Whitestone REIT for $19.00 per share, valued at approximately $1.7 billion, resulting in a change of control and the company's delisting from NYSE. The transaction included the merger of Whitestone with Merger Sub and the merger of Whitestone's operating partnership with Merger OP, with Whitestone ceasing to exist as a publicly traded entity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Whitestone REIT notified NYSE on July 14, 2026 of the completion of its acquisition by Ares Real Estate funds and requested cessation of trading and delisting via Form 25. Trading was suspended on July 14, 2026, and the company intends to file Form 15 to deregister under Section 12(g).
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-14
Item 5.02
Six board members and officers departed from Whitestone REIT effective as of the Company Merger Effective Time, as a direct consequence of the completion of Ares' acquisition of the company.
View raw filing on EDGAR →